CANF revenueFY2025$405.0K
- FY YoY
- -39.9%
- 5Y CAGR
- -11.9%
CANF revenue was $405.0K for fiscal 2025 (ended Dec 31, 2025), down 39.9% from fiscal 2024. Compound annual growth was -11.9% over 5 years. It rose in 3 of the last 9 fiscal years.
Can-Fite Biopharma Ltd (CANF) financials
For fiscal 2025 (ended Dec 31, 2025), Can-Fite Biopharma Ltd reported $405.0K of revenue and -$9.83M of net income.
- Revenue, FY2025
- $405.0K
- Revenue growth, YoY
- -39.9%
- Net income, FY2025
- -$9.83M
- Net margin
- -2426.7%
- Free cash flow, FY2025
- -$8.95M
- EPS, diluted, FY2025
- -$5.97
- Cash
- $5.53M
- P/S
- 12.58
- Market cap
- $5.1M
FY2016FY2025
FY2016FY2025
FY2016FY2025
CANF revenue and earnings growth
CANF net incomeFY2025-$9.83M
CANF net income was -$9.83M for fiscal 2025 (ended Dec 31, 2025), compared with -$7.88M in fiscal 2024.
CANF EPSFY2025-$5.97
CANF diluted EPS was -$5.97 for fiscal 2025 (ended Dec 31, 2025).
CANF free cash flowFY2025-$8.95M
CANF free cash flow was -$8.95M for fiscal 2025 (ended Dec 31, 2025), compared with -$7.64M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $405.0K | $674.0K | $743.0K | $810.0K | $853.0K | $763.0K | $2.03M | $3.82M | $789.0K | $165.0K |
| Research and development | $6.69M | $5.76M | $5.98M | $7.76M | $9.85M | $11.95M | $10.98M | $6.08M | $5.11M | $6.12M |
| Selling, general and admin | $3.66M | $3.05M | $2.96M | $3.14M | $3.85M | $317.0K | $3.06M | $3.16M | $2.87M | $2.73M |
| Operating income | -$9.95M | -$8.13M | -$8.20M | -$10.10M | -$12.84M | -$14.14M | -$12.01M | -$5.41M | -$7.18M | -$8.68M |
| Interest expense | $284.0K | $291.0K | $506.0K | -$222.0K | - | - | $693.0K | $1.20M | $621.0K | $55.0K |
| Pre-tax income | -$9.83M | -$7.88M | -$7.63M | -$10.17M | -$12.62M | -$14.44M | -$12.63M | -$6.57M | -$6.40M | -$8.36M |
| Income tax | - | - | - | - | - | - | - | $4.0K | $29.0K | $29.0K |
| Net income | -$9.83M | -$7.88M | -$7.63M | -$10.17M | -$12.62M | -$14.44M | -$12.63M | -$6.57M | -$6.34M | $8.26M |
| EPS, basic | -$5.97 | -$10.86 | -$17.92 | -$0.01 | -$0.03 | -$0.04 | -$0.14 | -$0.17 | - | - |
| EPS, diluted | -$5.97 | -$10.86 | -$17.92 | -$0.01 | -$0.03 | -$0.04 | -$0.14 | -$0.17 | - | - |
| Diluted shares | 1.6M | 725,309 | 426,111 | 815.7M | 553.1M | 358.4M | 85.9M | 38.9M | 32.5M | 27.7M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.53M | $4.83M | $4.28M | $2.98M | $4.39M | $8.27M | $2.70M | $3.62M | $3.50M | $8.12M |
| Short-term investments | $1.0K | $5.0K | $19.0K | $8.0K | $237.0K | $75.0K | $64.0K | - | - | - |
| Current assets | $9.44M | $8.98M | $9.91M | $9.16M | $20.07M | $9.40M | $7.14M | $7.90M | $6.66M | - |
| Total assets | $9.51M | $9.12M | $9.99M | $9.28M | $20.25M | $9.52M | $8.17M | $7.95M | $7.61M | - |
| Current liabilities | $2.73M | $2.05M | $2.02M | $2.50M | $2.73M | $1.27M | $3.27M | $3.12M | $1.75M | - |
| Total liabilities | - | - | - | - | - | - | $7.30M | $4.94M | $2.60M | - |
| Shareholders' equity | $5.59M | $5.44M | $6.24M | $4.47M | $14.38M | $6.07M | $2.44M | $3.02M | $2.98M | $5.96M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.95M | -$7.64M | -$8.44M | -$10.80M | -$9.86M | -$12.06M | -$11.08M | -$4.16M | -$8.97M | -$8.71M |
| Capital expenditures | $2.0K | $5.0K | $2.0K | $9.0K | $11.0K | $26.0K | $3.0K | $33.0K | $7.0K | $10.0K |
| Free cash flow | -$8.95M | -$7.64M | -$8.44M | -$10.81M | -$9.87M | -$12.09M | -$11.09M | -$4.19M | -$8.98M | -$8.72M |
| Investing cash flow | -$2.0K | $1.50M | $498.0K | $9.50M | -$14.51M | -$26.0K | -$3.0K | -$33.0K | -$29.0K | -$10.0K |
| Financing cash flow | $9.64M | $6.71M | $9.14M | - | $20.46M | $17.68M | $10.17M | $4.39M | $4.47M | - |
| Dividends paid | - | - | - | - | $2.59M | $715.0K | - | - | - | - |
| Stock-based compensation | $340.0K | $362.0K | $261.0K | $263.0K | $466.0K | $355.0K | $385.0K | $535.0K | $192.0K | $309.0K |
| Depreciation and amortization | $24.0K | $7.0K | $15.0K | $14.0K | $14.0K | $12.0K | $14.0K | $14.0K | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -39.9% | -9.3% | -8.3% | -5.0% | 11.8% | -62.5% | -46.8% | 384.2% | 378.2% | - |
| Operating margin | -2456.8% | -1206.2% | -1103.0% | -1246.4% | -1505.5% | -1853.1% | -590.9% | -141.7% | -910.6% | -5262.4% |
| Net margin | -2426.7% | -1169.1% | -1027.5% | -1255.9% | -1478.9% | -1892.9% | -621.3% | -172.0% | -803.4% | 5004.2% |
| Free cash flow margin | -2210.1% | -1133.8% | -1136.2% | -1334.6% | -1157.0% | -1584.4% | -545.6% | -109.6% | -1138.0% | -5287.3% |
| Return on equity | -175.8% | -145.0% | -122.3% | -227.5% | -87.7% | -237.8% | -517.0% | -217.9% | -212.4% | 138.5% |
| Return on assets | -103.3% | -86.4% | -76.4% | -109.6% | -62.3% | -151.7% | -154.5% | -82.6% | -83.3% | - |
| Current ratio | 3.46 | 4.38 | 4.90 | 3.66 | 7.35 | 7.41 | 2.18 | 2.53 | 3.80 | - |
Source: XBRL data Can-Fite Biopharma Ltd files with the SEC, latest filing dated Mar 26, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
CANF peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CANF | $405.0K | -39.9% | -$9.83M | -2426.7% | $5.1M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
CANF FAQ
8 questionsWhat is CANF revenue?
Can-Fite Biopharma Ltd (CANF) reported $405.0K of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 39.9% from the year before.Is CANF profitable?
No. Can-Fite Biopharma Ltd reported a net loss of $9.83M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does CANF have?
Can-Fite Biopharma Ltd reported $5.53M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is CANF revenue growing?
Can-Fite Biopharma Ltd's revenue changed -39.9% in fiscal 2025, to $405.0K. Its compound annual growth rate was -11.9% over 5 years.What is CANF free cash flow?
Can-Fite Biopharma Ltd generated -$8.95M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$8.95M less capital expenditures.What is CANF earnings per share?
Diluted earnings per share were -$5.97 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did CANF last report financial results?
The latest statements here come from Can-Fite Biopharma Ltd's 20-F filed on Mar 26, 2026, covering the period ended Dec 31, 2025.Where does this CANF financial data come from?
Quantisnow builds these statements from the structured XBRL data Can-Fite Biopharma Ltd files with the SEC. It is provided for information only and is not investment advice.